Bionano prelim Q4 rev $10.4-10.7M (+27-30% YoY); OGM base 326 (+36%)

Bionano Genomics, Inc.

2023-FY EPS reported -$6.81 revenue$36,116,000

Prelim Q4 2023 rev $10.4-10.7M vs $8.2M Q4 2022; FY rev $35.8-36.1M (+29-30%).
OGM installed base 326 as of year-end 2023, up 36% from 240 in 2022.
Q4 flowcell sales 7,980, up 67% from 4,781 in Q4 2022.
Cash, equivalents & securities ~$102.8M at Dec 31, 2023; $36.1M restricted.
Raised net $11.0M from ATM in Nov-Dec 2023 and $2.9M additional in Jan 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bionano Genomics, Inc. reported the fourth quarter of 2023 results: revenue in the range of $10.4 million to $10.7 million.

Period: the fourth quarter of 2023
Revenue: in the range of $10.4 million to $10.7 million
Result: preliminary results

Exact text from the filing

Revenues for the fourth quarter 2023 are expected to be in the range of $10.4 million to $10.7 million, an estimated increase of 27% to 30% compared to $8.2 million in the fourth quarter of 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bionano Genomics, Inc. reported the fiscal year ended December 31, 2023 results: revenue in the range of $35.8 million and $36.1 million.

Period: the fiscal year ended December 31, 2023
Revenue: in the range of $35.8 million and $36.1 million
Result: preliminary results

Exact text from the filing

Full year 2023 revenue is expected to be in the range of $35.8 million and $36.1 million, an estimated increase of 29% to 30% compared to full year 2022.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-001200

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.